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Abstract
Background: Current evidence supports a diverting stoma in patients undergoing low anterior resection with total
mesorectal excision for rectal cancer as it reduces clinical severity of anastomotic leakage. However, relevant stoma
morbidity after rectal cancer surgery exists and has a significant impact on quality of life. Moreover, a diverting stoma
has an influence on completeness of chemotherapy but it remains unclear in which way. There is no evidence regarding
optimal timing for stoma closure in relation to adjuvant chemotherapy. Two randomised controlled trials have studied
early stoma closure after low anterior resection in patients with rectal cancer, one of them showing that early closure
around day 8 after resection is possible without increasing morbidity.
Methods/Design: CoCStom is a randomised multicentre trial comparing completeness of adjuvant chemotherapy as
primary endpoint after early (8–10 days after resection, before starting adjuvant therapy) versus late (~26 weeks after
resection and completion of adjuvant therapy) stoma closure in patients with locally advanced rectal cancer undergoing
low anterior resection after neoadjuvant therapy. After exclusion of post-operative anastomotic leakage 257 patients from
30 German hospitals are planned to be included in order to assure a power of 80 % for the confirmatory analysis of at
least 214 evaluable cases. An absolute increase of 20 % for the rate of completely administered adjuvant chemotherapy
is regarded as a clinically meaningful step forward and serves as basis for sample size calculation. Quality of life,
stoma-related complications, individual completeness of chemotherapy rate, percentage of patients stopping
adjuvant therapy or undergoing dose modifications or delay, oncological outcomes, cumulative days of hospitalisation
and number of readmissions, rate of symptomatic anastomotic leaks after stoma closure, mortality, post-operative
complications and toxicity of adjuvant chemotherapy are secondary endpoints.
Discussion: The CoCStom trial aims to clarify optimal timing of stoma closure in the context of adjuvant chemotherapy.
Depending on the results of the trial, patients could benefit either from early or late stoma closure in regard to long
term oncological survival due to a higher rate of completeness of adjuvant chemotherapy treatment and thus better
effectiveness.
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Background
Low anterior resection (LAR) is the procedure of choice
for rectal cancer of the middle and lower third [1, 2]. An
anastomosis performed close to the pelvic floor is associ-
ated with a relevant risk of anastomotic leakage (3–17 %),
which contributes to mortality [3]. Based on level-1 evi-
dence a diverting stoma effectively reduces the rate of
symptomatic anastomotic leakage [4].
However, a diverting stoma also causes morbidity,
which may affect nearly half of all patients as shown in
an analysis of patients with protective stoma for distal
colonic anastomosis [5]. Stoma-related morbidity in-
cludes high-output stoma, stoma prolapse, small bowel
obstruction and wound infection and has been evaluated
in several studies [5–7]. Moreover, a stoma may impair
quality of life (QoL). The global QoL as well as the phys-
ical functioning and role scores are negatively influenced
by stoma after LAR with total mesorectal excision
(TME) as shown in two prospective observational longi-
tudinal studies of 22 [8] and 24 patients [9] respectively.
These scores and additionally the mental health im-
proved 6 weeks after ileostomy closure. Contrarily, 23
patients receiving a high anterior resection without
stoma had higher QoL scores postoperatively compared
to preoperatively [9].
Very little evidence regarding the optimal timing for
stoma closure was found despite an extensive systematic
search in relevant literature databases and trial registries.
Our prospective multicentre pilot study investigating the
timing of stoma closure and longitudinal QoL before
LAR with TME, before stoma closure and 6 months
after stoma closure on 171 patients from 17 participating
German surgical centres showed that this is in median
performed 5.1 months after creation, with a wide range
(0.6–32 months) [10].
Earlier stoma closure is feasible with low morbidity and
no mortality as a pilot study demonstrated by closing the
stoma 11 days after tumour resection [11]. Finally, a pro-
spectively randomised multicentre trial with 186 patients
confirmed that stoma closure on day 8, during the same
hospitalisation, is possible without increase of the peri-
operative complication rate. In this study, which reflects the
best available evidence, the overall postoperative complica-
tion rate was significantly lower in the early closure group
(small bowel obstruction early vs. late: 3 vs. 16 %, p = 0.002
and medical complications: 5 vs. 15 %, p = 0.021) [6]. The
hospitalisation period was also significantly shorter in the
early stoma closure group (p = 0.013) but there was no dif-
ference in QoL (p = 0.566). Major drawback of this study is
that there is no data on administered adjuvant chemother-
apy. The only larger, albeit retrospective, study investigating
stoma related complications and postoperative morbidity in
120 patients with colorectal carcinoma undergoing colorec-
tal resections in regard to adjuvant chemotherapy showed a
trend toward fewer complications (12.5 %) if stoma closure
was performed early (i.e. before starting adjuvant chemo-
therapy) rather then during (42.9 %) or after (21.2 %)
chemotherapy [7].
In contrast, an early closure of the stoma may also
negatively influence the completeness of chemotherapy
(CoC) due to complications like symptomatic anasto-
motic leakage or LAR syndrome. The latter is a well-
known clinical condition occurring after deep anterior
rectal resection potentially severely impairing QoL in
these patients [12, 13]. This usually becomes evident
during the first months after stoma reversal and may
also aggravate side-effects of chemotherapy, again result-
ing in less patients receiving all cycles of planned
chemotherapy.
Timing of diverting stoma closure in advanced rectal
cancer has also not yet been adequately investigated in
the setting of adjuvant chemotherapy. Moreover, no ran-
domised studies specifically investigating the influence
of CoC on overall survival (OS) in patients having
undergone rectal resection for rectal cancer have yet
been published. We re-analyzed the data from our
phase-III study comparing 5-FU and capecitabine in the
perioperative treatment of patients with stage II and III
rectal cancer with regard to influence of CoC on survival
[14]. CoC in this trial was associated with a significant
improvement of 3-year disease free survival (DFS) as
well as 5-year OS. Therefore, since adjuvant chemother-
apy is considered to improve long-term survival in
nodal-positive (stage III) disease and recommended as
standard treatment in the German S3-guidelines [15, 16]
it is suitable to consider CoC as primary endpoint in a
prospective randomised clinical trial. Moreover, in order
to improve the rates of completed adjuvant chemother-
apy treatment in rectal cancer, it is highly patient rele-
vant to investigate the influence of a stoma.
In conclusion, the optimal timing for stoma closure
with regard to CoC remains controversial. It seems
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advantageous to close the stoma as early as possible, but
on the other hand early closure may result in more com-
plications which may impair the administration of all
planned cycles of adjuvant chemotherapy.
Methods/Design
Trial design
CoCStom is an investigator-initiated prospective rando-
mised open-label multicentre trial with two parallel study
groups.
Patient population
Patients with rectal cancer stadium UICC II-III undergo-
ing low anterior resection with diverting stoma after neo-
adjuvant therapy and planned adjuvant chemotherapy will
be included in the trial. A detailed overview of all eligibil-
ity criteria is given in Table 1.
Scheme of intervention
Only centres with a special focus on colorectal surgery per-
forming at least 20 LARs per year for rectal cancer (expert-
ise based trial) in accordance to the German guidelines
(e.g. adherence to the principles of total mesorectal exci-
sion) can take part in the CoCStom trial. This corresponds
to certification requirements for colorectal cancer centres
of the German Cancer Society [17].
In order to minimise performance bias, LAR within the
study is performed only by surgeons with a minimum ex-
perience of 20 LARs for cancer (‘life-time experience’). In
addition, surgeons need to have an adequate experience in
performing the investigated stoma reversal approach. The
recommended minimum number of stoma closures is 10.
The individual surgeon’s experience will be documented.
Each study centre provides at least one surgeon meeting
these requirements. Stoma closure will be performed,
according to the centre standard of care, before (ex-
perimental) or after completion (standard) of adjuvant
chemotherapy.
The adjuvant chemotherapy will be performed accord-
ing to the S3-guidelines for colorectal cancer [15] and
recent clinical evidence [14, 18, 19] using 5-fluorouracil-
(5-FU) and oxaliplatin-based regimes.
Recruitment and trial timeline
Recruitment of the patients has started in December 2013.
The duration of the trial for each patient is expected to be
24 months including follow-up at 7 and 24 months after
randomisation. The duration of the entire trial is expected
to be 69 months (Fig. 1).
Assignment of intervention and randomisation
Patients should be screened as soon as the tumour stage
(UICC II-III) is confirmed and the neoadjuvant therapy
(chemoradiation or 5×5 Gy schedule) has been defined.
All patients having undergone neoadjuvant therapy for
clinically staged cT3/4 Nx or cTx N+ rectal cancer (staged
with endorectal ultrasonography + CT or endorectal ultra-
sonography +MRI), LAR with TME and protective stoma
and after having given written informed consent will be
registered for the trial. The randomisation will take place
around 7 days after LAR by central online registration,
after exclusion of anastomotic leakage by endoscopy and/
or radiographic enema. Patients will be allocated to two
groups, early group (experimental) - stoma closure
between day 8 and 10 after LAR before starting the adju-
vant chemotherapy and late group (standard) - stoma
closure after adjuvant chemotherapy around week 26 after
LAR. A central computer-generated block-randomisation
with alternating block sizes will be performed by web-
randomisation within the electronic case report forms
Table 1 Inclusion and exclusion criteria
Inclusion criteria Exclusion criteria
▪ Temporary diverting stoma (independent from the stoma type) ▪ ASA >3
▪ Elective curative LAR with TME (laparoscopic, open or converted)
after neoadjuvant therapy (long course chemoradiation or short-term
radiotherapy - 5 × 5 Gy) for UICC II-III rectal cancer
▪ Inflammatory bowel disease
▪ No anastomotic leakage (endoscopic or contrast enema assessment
of the anastomosis around day 7 after LAR)
▪ Contraindication to adjuvant chemotherapy arising after rectal
cancer resection [15]
▪ Indication to undergo adjuvant chemotherapy (according to current
German guidelines the pre-therapeutic stage serves as basis for the
adjuvant treatment decision) [15]
▪ Disease progress to UICC IV under neoadjuvant therapy
▪ Patient has given written informed consent ▪ Immunocompromised patients (HIV-positive, patients currently under
chemotherapy for other diseases or patients under immunosuppressive
therapy, e.g. Prednisolone >10 mg)
▪ Age ≥18 years ▪ Participation in another intervention-trial with interference of
intervention and outcome of this study
▪ Patient is able to cooperate (ability of subject to understand character
and individual consequences of the clinical trial)
HIV human immunodeficiency virus
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(eCRF) system in order to ensure an adequate random al-
location. There will be stratification by centre.
Interventions and trial flow
The stoma may be closed either by a direct suture of the
anterior wall or by an end-to-end, side-to-side or end-
to-side anastomosis after a segmental resection of the
bowel (stapler or hand suture) according to the centre’s
standard of care.
The following 5-FU- and oxaliplatin-based adjuvant
chemotherapy schedules are allowed:
 four cycles of bolus 5-FU 500 mg/m2 (days 1–5,
repeated at day 29) or bolus 5-FU 350 mg/m2 plus
folinic acid 20 mg/m2 (days 1–5, repeated at day 29),
 five cycles of capecitabine 2500 mg/m2 (days 1–14,
repeated at day 22),
 XELOX-Schedule – five cycles of capecitabine
2000 mg/m2 (days 1–14, repeated at day 22) plus
oxaliplatin 130 mg/m2 (day 1, repeated at day 22),
 De Gramont-Schedule – eight cycles of bolus 5-FU
400 mg/m2 (day 1, repeated at day 15) plus 5-FU
600 mg/m2 over 24 h (days 1 and 2, repeated at day
15) plus folinic acid 200 mg/m2 (day 1, repeated at
day 15),
 FOLFOX6-Schedule – eight cycles of bolus 5-FU
400 mg/m2 (day 1, repeated at day 15) plus 5-FU
2400 mg/m2 over 46 h (day 1, repeated at day 15)
plus folinic acid 400 mg/m2 (day 1, repeated day 15)
plus oxaliplatin 85 mg/m2 (day 1, repeated at day 15).
In both arms, adjuvant chemotherapy starts within 4
(earliest) and 12 (latest) weeks after randomisation, unless
unexpected complications occur. Each participating insti-
tution should preferably select one of the regimens for
their patients, before randomisation, in order to avoid bias.
When a regimen has been started in an individual patient,
this regimen should be continued throughout the study
period. Administration of chemotherapy and regular blood
tests as well as the treatment of adverse events (AEs) will
be done according to the standard operating procedure
implemented in the various oncological departments.
Concomitant therapies (e.g. antiemetics) are allowed in
accordance to local standard treatment but dose reduction
should be done according to the protocol and to NCI-
CTCAE criteria v.4.03 [20] unless it is not in the best
interest of the treated patient (Table 2). Concurrent
administration of any other anti-cancer therapy is not
permitted during trial participation. The treatment and
prophylaxis of some AEs such as neuropathy [21], hand-
foot skin reaction [22], antiemetic treatment [23], chemo-
therapy induced diarrohea [24], and high-output stoma
[25] should be performed according to the international
standards.
Description of the trial visits
Trial visits will be performed in the corresponding clin-
ical centres (surgical and oncological departments). Ex-
amples for trial visits for chemotherapy regimen with
eight cycles are given as Additional file 1 and Additional
file 2.
• exclusion criteria
n = 40 (10%)
• no compliance
n = 40 (10%)
• no informed consent
n = 64 (16%)
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Fig. 1 Expected patient flow from screening to final analysis. Early closure group: stoma closure and first chemotherapy (CTx) will be done around 2 days
and within 4 (earliest) to 12 (latest) weeks respectively after randomisation. Late closure group: first CTx will be done within 4 (earliest) to 12 (latest) weeks
after randomisation; stoma closure will be done 4 weeks after end of CTx. Randomisation will be performed around day 7 after LAR (after exclusion of an
anastomotic leakage). To reach the statistically calculated goal of 257 recruited patients, at least 128 patients have to be randomised into each trial arm. W:
weeks, M: months, OP: operation, *: after randomisation
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Outcome measures and definitions
CoC is defined as primary endpoint and can be assessed
objectively immediately after completion of treatment. CoC
will be measured 28 weeks after randomisation. This point
of time reflects the status after planned complete chemo-
therapy administration in both trial groups and after the
stoma has already been closed.
CoC will be assessed by determining the proportion of
the randomised patients which complete all planned
cycles of adjuvant chemotherapy. Secondary endpoints
and their definition are presented in Additional file 3.
Data management
Data must be reported on eCRF. All protocol-required
information collected during the trial must be entered by
the investigator or authorised staff members as soon as
possible after information is collected. Any outstanding
entries must be completed immediately after the final
examination. It is the responsibility of the investigator to
review and sign the eCRFs.
Compliance/rate of loss to follow-up
In order to maximise the number of participating patients
to the study, disabled patients may be visited by a “flying
study nurse”. Phone interviews are only exceptionally
allowed.
A rate of 10–20 % of drop-outs and losses to follow-
up are considered in order to have a sufficient power in
the per-protocol analysis.
Safety assessments and reporting of adverse events
Analysis of safety-related data is performed by calcula-
tion and descriptive comparison of the rates of AEs and
serious adverse events (SAEs) based on all patients re-
ceiving at least one protocol-specified procedure.
An AE is defined as any untoward medical event in a
patient which occurs following surgery or chemotherapy.
A SAE is defined as any AE that results in death, immedi-
ately life threatening event, hospitalisation or prolongation
of hospitalisation, persistent or significant disability or in-
capacity. SAEs will be classified according to intensity
(mild, moderate, severe, life-threatening, death), outcome
(recovered completely, recovered with sequelae, not re-
covered with or without therapy of SAE, death, unknown),
and causality (doubtful, possibly related, probably related,
definitely related, not assessable).
The investigator must report every event meeting the
protocol definition of an SAE to the coordinating inves-
tigator until the next working day after having become
aware of the event.
Statistical methods
Sample size calculation
The sample size calculation is based on the analysis of the
primary endpoint, completeness of adjuvant chemother-
apy. According to our recent randomised phase III trial on
perioperative treatment of stage II and III rectal cancer, a
total of 61.7 % (capecitabine) and 57.5 % (5-FU), respect-
ively, started adjuvant chemotherapy, and 45.7 and 40.0 %
had their scheduled cycles completed [14]. These data are
consistent with the findings in other studies investigating
perioperative chemo (radio)therapy in rectal cancer.
Based on this data, we assume a CoC rate of 42 % for
the standard patient group with a diverting stoma during
adjuvant chemotherapy. A 20 % absolute increase of
CoC (42–62 %) is regarded as a clinically meaningful
step forward. In order to significantly detect this differ-
ence on a type I error level of 5 % (two-sided) with a
power of 80 %, a sample size of 107 is required in each
arm based on the application of Fisher’s exact test. The
Mantel-Haenszel procedure stratifying for centre will be
used for the primary hypothesis of the trial.
Any major deviation from these CoC rate assumptions
will lead to increased power, if the delta of 20 % is retained.
According to the primary endpoint, the number of losses in
the intention-to-treat (ITT) population should be minimal.
A rate of 10–20 % of drop-outs and losses to follow-up is
expected. Thus, about 260 patients should be randomised
to ascertain sufficient power in the per-protocol analysis.
Stratification by centre is foreseen, since centre-specific
characteristics such as the quality of surgery, patient guid-
ance with respect to chemotherapy compliance, etc. may
have a major influence on important outcome parameters.
Table 2 Dose modification scheme adapted to severity of adverse events
Grade 2 Grade 3 Grade 4
1. occurrence Withold therapy until AE has
resolved to grade 0–1.
Withold therapy until AE has
resolved to grade 0–1.
Withold therapy until AE has
resolved to grade 0–1.
Continue with 100 % of the
starting dose.
Continue with 75 % of the
starting dose
Continue with 50 % of the
starting dose
2. occurrence Withold therapy until AE has
resolved to grade 0–1.
Withold therapy until AE has
resolved to grade 0–1.
Stop treatment.
Continue with 75 % of the starting dose. Continue with 50 % of the starting dose.
3. occurrence Stop treatment Stop treatment
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Definition of analysis population
Patients who were enrolled although they unequivocally
did not fulfil the selection criteria of the trial a priori
(“non-eligible”) will be excluded from the statistical ana-
lysis, in accordance with ICH recommendations [26].
All other patients will primarily be evaluated in an
ITT analysis according to allocation by randomisation. A
second analysis (“per protocol”) of the primary endpoint
will include only patients with full documentation on
the amount of adjuvant chemotherapy received (i.e. in-
cluding patients with a reliable documentation of no or
incomplete adjuvant treatment).
All patients having received at least one application of
protocol-defined therapy are evaluable for safety.
Analysis variables and statistical methods
 Primary analysis
The character of the primary analysis is confirmatory.
The analysis is based on the ITT population using the
ITT principles (dropouts and missing data will be counted
as failures). For the analysis of the primary endpoint, the
Mantel-Haenszel stratified test will be used. Correspond-
ing 95 % confidence interval (CI) will be calculated for the
CoC rates in both groups and for the rate difference and
odds ratio (OR).
 Sensitivity analysis
The primary endpoint will be additionally analysed based
on the per-protocol set comprising all patients with full
documentation on the amount of adjuvant chemotherapy
received. A multivariate analysis (logistic regression model)
will be applied to account for the effect of potential prog-
nostic factors such as for example age, performance status,
location of the primary tumour, and T-stage.
 Secondary analysis
All secondary analyses have only exploratory character.
P-values may only be used descriptively. All variables
will be described at least by the number of observations,
mean, standard deviation, median, minimum and max-
imum, or counts/percentages, as appropriate.
QoL data will be scored according to the algorithm de-
scribed in the EORTC QLQ-C30 scoring manual [27].
While data on all functional and symptoms scales will be
described, formal comparisons are going to focus on glo-
bal QoL and symptoms related to the impact of chemo-
therapy and surgery on rectal cancer patients specifically
(overall QoL, diarrhoea, constipation, vomitting).
In case of disease-free survival, local recurrence-free sur-
vival and distant recurrence-free survival Kaplan Meier
survival curves for the groups will be presented and com-
pared by the log rank test. Further secondary endpoints
will be compared using a Wilcoxon-Mann–Whitney-U test
or tests for contingency tables, as appropriate according to
the type of data.
No interim analysis is planned. However, while the main
statistical analysis is performed, as soon as documentation
of post-operative therapy is completed in all patients at
about 7 months post randomisation, a second analysis on
long-term endpoints is performed about 1.5 years later.
Individual trial termination
Patients may be withdrawn from the trial any time at
their own request without giving reasons for their deci-
sion or if, in the investigator’s opinion, continuation of
the trial would be detrimental to the patient’s well-being.
Premature closure of the trial
The trial may be prematurely closed by the principal in-
vestigator in consultation with the steering committee. If
the termination of the trial becomes necessary, the steer-
ing committee will discuss this issue with the independent
data safety and monitoring board (DSMB). Reasons that
may necessitate a termination of the trial include a poten-
tial health hazard caused by the trial treatment indicated
by incidence or severity of SAEs in this trial, unsatisfactory
patients’ enrolment, severely inaccurate and/or incomplete
data recording or external evidence demanding a termin-
ation of the trial. The Ethic Committees will be informed.
Trial organization and administration
Monitoring
All participating centres were personally trained and intro-
duced into study-specific procedures during initiation visit.
Regular on-site monitoring visits are planned at all sites.
For at least 5 % of all subjects a 100 % clinical source data
verification (SDV) for all clinical items is planned. The
extent of further SDV and/or the frequency of monitoring
visits will be adapted for individual centres depending on
the quality of data or if common protocol violations are
observed. In addition to the SOPs and to the trial protocol,
procedures will be predefined in a study-specific monitor-
ing manual and an eCRF manual. Queries will be issued by
the monitor as well as the data manager and have to be
answered by the investigators within a short time to avoid
errors in data capture or entry being carried forward.
Steering committee
The steering committee supervises the conduct of the
trial and issues recommendations for early termination,
modifications or continuation of the trial, if necessary. It
comprises seven members (three surgeons, two oncolo-
gists, radio-oncologist and statistician).
Sandra-Petrescu et al. BMC Cancer  (2015) 15:923 Page 6 of 9
Data and safety monitoring board (DSMB)
To enable an independent risk assessment for treatment,
potentially related SAEs will be noted and periodically (at
least once a year during the first 24 months) assessed by
the independent DSMB. Clinical monitoring will supervise
patient’s safety and integrity of the clinical data. DSMB is
an independent committee of 3 members (a surgeon, a
radio-oncologist, and a statistician) whose task is to review
the status of the clinical trial and make recommendations
to the clinical research group concerning trial conduct,
modification and/or publication. DSMB members will be
asked to give advice on whether the accumulated safety
data − notably SAEs − from the trial, together with results
from other relevant trials, justify continuing recruitment
of further patients. A decision to discontinue recruitment,
in all patients or in selected subgroups, will be made only
after discussion of the issue with the steering committee.
Ethical and legal aspects
The trial protocol, informed consent document and all
trial specific documents were approved by the Ethics
Committee II of the Medical Faculty of Mannheim,
University of Heidelberg. Additionally, an ethical ap-
proval has been obtained at all participating centres
(Additional file 4). The responsible investigator will en-
sure that this study is conducted in agreement with the
Declaration of Helsinki (Tokyo, Venice, Hong Kong,
Somerset West, Edinburgh, Seoul and Fortaleza amend-
ments) [28] and the laws and regulations of the coun-
try. The protocol has been written, and the trial will be
conducted according to the principles of ICH Harmo-
nized Tripartite Guideline for Good Clinical Practice
[26]. Patient data in the eCRF will be pseudonymised.
Benefit-risk assessment
Benefit-risk assessment was critically reviewed. Potentially,
early stoma closure could result in more clinically relevant
leaks of the rectal anastomosis as the time period for
complete anastomotic healing is shorter. In order to
exclude or minimize the risk of developing a clinically
relevant leak of the rectal anastomosis after stoma closure
the appropriate investigations confirming a healed anasto-
mosis, which are usually done before late stoma closure,
are mandatory also for early stoma closure. Several stud-
ies, including a large randomized controlled study, have
not shown an increased risk for symptomatic leaks of the
rectal anastomosis after early stoma closure [6, 8, 11].
Healing of the small bowel anastomosis after stoma clos-
ure may be impaired in the early group, because tissues
may still be more friable such a short time after laparot-
omy. Again, several studies, including a large randomized
controlled study, have not shown an increased complica-
tion risk for patients undergoing early stoma closure. On
the other hand stoma closure may be more easy and faster
as scaring may not yet be so pronounced less than ten
days after stoma creation. Moreover, multiple complica-
tions may occur after stoma placement (e.g. kidney failure,
prolapse, etc.), which may be minimized by early stoma
closure. Finally, early stoma closure may have an impact
on CoC potentially resulting in more patients receiving
the full or at least a higher dose of scheduled chemother-
apy which in turn could improve the oncological progno-
sis. Several studies including an analysis of our own data
within a randomized controlled trial have shown that in-
complete chemotherapy cycles and reduced dosages influ-
ence oncological outcome [14, 29, 30]. Therefore, even if a
small to moderate increase of complications occurred due
to early stoma closure this may be acceptable in order to
improve overall outcome of patients.
Discussion
Whether the time point of stoma closure influences the
complete administration of the planned adjuvant chemo-
therapy, in patients with locally advanced rectal cancer
undergoing LAR with TME after neoadjuvant therapy,
remains unclear. Besides local complications stoma can
have a negative impact on the patient’s psychological
state since the mental health score was shown to be
impaired in the presence of a stoma [9]. After tumour
resection, stoma has a significant influence on the pa-
tients’ well being [9], affects them emotionally [8] and
thus has a major impact on their compliance with the
treatment. Some patients insist on stoma closure before
the end of adjuvant chemotherapy cycles which may lead
to a delay of the remaining therapy and may also in-
crease complication rates [7]. Other patients stop ther-
apy prematurely due to presence of a stoma [31].
That early stoma closure is an important issue in the
complex therapy of rectal cancer patients is confirmed also
by a newly started prospectively randomised Scandinavian
multicentre study [32]. It compares early closure versus
standard treatment (8–13 days vs. 12–26 weeks after
surgery) with postsurgical morbidity as primary endpoint,
QoL and the socio-economic effects of early closure as
secondary endpoints. But this trial does not investigate
CoC which therefore will remain an open question with
high clinical relevance for the individual patient.
It is of major importance that patients undergo all
chemotherapy cycles in order to maximally benefit from
adjuvant treatment [30] but several studies show that not
all patients are able to receive all cycles of the planned ad-
juvant therapy [14, 29, 30]. This may be due to suboptimal
compliance with the therapy which can be explained by
chemotherapy toxicity and postoperative complications.
Since early stoma closure is possible without increase
in preoperative mortality and the complete administra-
tion of the planned chemotherapy cycles potentially
improves the oncological outcome, it remains to be
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determined how early stoma closure influences CoC.
This is the primary goal of the CoCStom trial and will
contribute to clarifying how the largest benefit from ad-
juvant therapy can be gained for the affected patients.
Therefore, CoC is a suitable primary endpoint and has
high clinical relevance for the individual patient.
The trial may also have relevant socio-economic impact
as early closure, if shown as equivalent or even superior,
can cut costs due to reduced need for stoma care products
and also due to a shorter overall period of hospitalisation.
CoCStom is a combined surgical-oncological trial. Its
success requires a very good collaboration between sur-
geons and oncologists and the results may also have an im-
pact on current guidelines as early closure of a stoma is
currently not regarded as standard of care. Furthermore, re-
sults may also influence the “German DRG-System” on
which is based the financing of medical in-house proce-
dures. Presently, ileostomy closure within the same hospital
stay as the rectal resection is not additionally reimbursed in
contrast to late stoma closure in a second hospital stay.
Trial status
Recruitment has started in December 2013. As of August
28th, 2015, 75 patients have been randomized.
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